Immunocore

#4770

Rank

$1.57B

Marketcap

United Kingdom

Country

Leadership team

Dr. Bahija Jallal Ph.D. (CEO & Director)

Mr. Brian R. Di Donato M.B.A. (CFO & Head of Strategy)

Ms. Annelise Vuidepot Ph.D. (CTO and Head of Pipeline & Platform Research)

Products/ Services

Biotechnology, Health Care, Medical, Pharmaceutical

Number of Employees

100 - 500

Headquarters

Abingdon, Oxfordshire, United Kingdom

Established

2008

Company Registration

SEC CIK number: 0001671927

Revenue

100M - 500M

Traded as

IMCR

Social Media

URL

https://www.immunocore.com

Overview

Location

Recognition and Award

References

Summary

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company's programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

History

Immunocore was founded in 2008 as a spinout of MediGene AG, which acquired Avidex in 2006. The core technology was spun out of Oxford University in 1999 by Dr Bent Jakobsen into Avidex Ltd.In July 2015, Immunocore announced the completion of an initial $320 million private financing round, Europe's largest ever financing round by a private life sciences company. Fidelity Management & Research Company, Woodford Investment Management, Malin Corporation, Eli Lilly and Company, and RTW Investments all participated in this fundraise along with other unnamed investors and existing shareholders.In September 2017, the Bill & Melinda Gates Foundation announced a $40 million investment in Immunocore to accelerate the development of Immunocore’s ImmTAV and ImmTAB therapeutics.In March 2020, Immunocore announced the closing of its $130 million Series B private financing round. In January 2021, Immunocore announced the closing of its $75 million Series C round. Immunocore went public in February 2021, with closing announced on February 9, 2021.

Mission

Immunocore strives to develop life-transforming T-cell receptor-based therapies for the treatment of cancer and other serious diseases with high unmet medical needs.

Vision

To be the preeminent company leading the development of a new generation of life-transforming medicines.

Key Team

Clayton Robertson (Head of Investor Relations)

Ms. Lily Hepworth (Gen. Counsel & Company Sec.)

Ms. Amy Judge-Prein (Chief Compliance Officer)

Mr. Sébastien Desprez (Head of Communications)

Ms. Tina St. Leger (Chief HR Officer)

Dr. David Berman M.D., Ph.D. (Head of R&D)

Ms. Debra Nielsen (Chief of Staff)

Recognition and Awards

Immunocore has been the recipient of numerous awards and accolades for its innovation, technological advancements and leadership within the biopharmaceutical sector.